Stock List

Search by Ticker



Biogen Inc. (NASDAQ:BIIB)
Stock Analysis

▼ -0.05%-0.14

Stock Analysis

The following stock analysis is based on 9 years of data (i.e. since Mar 17, 2014). All the stock history has been downloaded.

Stock Exchange

Biogen Inc. trades on the NasdaqGS exchange in USD dollars.


It is in the sector.

Current Status of Biogen Inc.

It is currently trading at $267.77 ($267.91 the previous day).


The next reporting date is in 35 days (2023 04 26).

CNN estimates profits for the upcoming quarter will be $3.39 per share ($2.4B). The current Canada / US exchange rate is 1.36648.

Over the past 12 months, $0 worth of shares have been purchased and $5893689 worth of shares have been sold by insiders.

Will This Trend Continue?

The year over year average increase is -1.6% per year assuming steady exponential growth. The actual 5 year average is -3.68. Details on the individual increase in one year intervals is provided below.

Past PerformanceAverage PricePercent Change
1 year237.14689393939-17.7- Below Average
2 year288.242243589743.8+ Above Average
3 year277.677154545459.6+ Above Average
4 year253.43952098765-18.7- Below Average
5 year311.681901140684.6+ Above Average
Biogen Inc. is projected by analysts to get to $324.00 within the next 12 months (21%), but preticted targets range from as high as $388.00 (44.9%) and as low as $249(-7%).


The worst drop it has had in recent years is -59.6%. It has a shape to the stock curve, which means

Stock shape test


The P/E value is 12.6.

Tradingview BuySell Widget

Yahoo News Feed

Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit

Tue, 21 Mar 2023 12:59:25 FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's (NASDAQ: BIIB) ALS drug tofersen. FDA staff, citing a briefing document, said Biogen's investigational ALS drug might have a "clinical benefit" ...... Read Full Article

Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo

Mon, 20 Mar 2023 16:25:22 Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. ...... Read Full Article

UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval

Mon, 20 Mar 2023 13:51:30 The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval. A panel ...... Read Full Article

Should You Buy Biogen Before a Big July Decision?

Sun, 19 Mar 2023 09:30:00 Over time, Biogen (NASDAQ: BIIB) created a true success story. Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market. Now, though, Biogen may have found that new growth source.... Read Full Article

Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?

Fri, 17 Mar 2023 15:30:03 Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.... Read Full Article

Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 27% Undervaluation?

Fri, 17 Mar 2023 12:00:19 Key Insights The projected fair value for Biogen is US$362 based on 2 Stage Free Cash Flow to Equity Biogen's US$265...... Read Full Article

Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments

Thu, 16 Mar 2023 18:00:51 The Alzheimer's Association has launched a grassroots lobbying campaign while deploying 1,000 people, either patients or caring for someone with the disease, to meet with all 535 members ...... Read Full Article

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

Thu, 16 Mar 2023 12:43:12 Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.... Read Full Article

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

Thu, 16 Mar 2023 10:30:00 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a ...... Read Full Article

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

Wed, 15 Mar 2023 22:00:10 Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.... Read Full Article

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Tue, 14 Mar 2023 22:15:10 In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.... Read Full Article

The VA Will Pay for Leqembi. It’s a Step in Right Direction for Biogen.

Tue, 14 Mar 2023 14:52:00 The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy.... Read Full Article

1 Reason to Buy Biogen Stock, and 1 Reason to Sell

Tue, 14 Mar 2023 14:23:00 Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons. U.S. approval of Biogen's Aduhelm for treating Alzheimer's disease (AD) ...... Read Full Article

Veterans Health to cover Eisai, Biogen’s new Alzheimer’s drug

Tue, 14 Mar 2023 12:57:00 Eisai Co. Ltd. (JP:4523) said Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer’s disease treatment it developed with Biogen Inc. (BIIB) that received an accelerated approval in January. The drug is not broadly covered at this ...... Read Full Article

Biogen Appoints Chuck Triano as Head of Investor Relations

Tue, 14 Mar 2023 11:30:00 CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial ...... Read Full Article

Veterans Affairs to Be First Major Insurer to Cover Alzheimer’s Drug Leqembi

Mon, 13 Mar 2023 21:05:00 Eisai ’s new Alzheimer’s disease drug Leqembi will be covered by the U.S. Department of Veterans Affairs, the first major insurer to agree to pay for the drug since its approval by U.S. regulators earlier this year. ...... Read Full Article

UPDATE 1-US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi

Mon, 13 Mar 2023 21:01:58 Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease. The VA did not ...... Read Full Article

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed

Thu, 09 Mar 2023 21:05:27 Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.... Read Full Article

Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study

Thu, 09 Mar 2023 14:33:02 Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.... Read Full Article

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Wed, 08 Mar 2023 23:00:11 Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.... Read Full Article